WHWK Whitehawk Therapeutics Inc
USHealthcareAs of 2026-07-10 16:00
Why WHWK matters now
Whitehawk Therapeutics Inc (WHWK) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.97 with +2.85% on the session and $196.3M in market capitalization; recent performance reads 1-month +8.60% and YTD +82.64%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.2M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -44.8%.
The latest indexable market news headline is "Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $7.00; recent insider activity includes Aghazadeh Behzad filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.63
P/S
0.00
EV/EBITDA
-1.59
DCF Value
$-4.39
FCF Yield
-44.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-79.6%
ROA
-91.0%
ROIC
-105.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.2M | $-0.32 |
| Q4 2025 | $0.00 | $-23.3M | $-0.34 |
| FY 2025 | $7.1M | $-20.6M | $-0.33 |
| Q3 2025 | $0.00 | $-17.7M | $-0.26 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.77
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.